French drug industry kicked off key government committee
This article was originally published in SRA
Executive Summary
The French drug industry body Leem is to lose its seat on a key government committee that makes recommendations on the medical added value of new medicines. This appears to be the latest manifestation of the government's intent to proscribe all industry involvement in regulatory decision-making following the 2011 drug Mediator affairs.